Mandate

Vinge advises Veoneer in connection with its USD 600 million capital raise

Veoneer, Inc. (“Veoneer”) has completed a USD 600 million capital raise, consisting of two concurrent offerings of USD 420 million of shares of common stock and USD 180 million aggregate principal amount of convertible senior notes due 2024.

Veoneer is listed on the New York Stock Exchange (NYSE:VNE) and on Nasdaq Stockholm (SSE: VNE SDB). 

Vinge advises Veoneer in relation to Swedish law. Vinge’s team mainly consist of Göran Nyström, Erik Sjöman, Malte Hedlund, Astrid Isberg, Stephanie Stiernstedt, Viktor Bergsten and Anders Sundin Lundberg. Maria Schultzberg advises on tax issues. 
 

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025